利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

86 条记录 (耗时 0.041 秒)

    Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
    12.
    发明申请
    Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors 有权
    作为Fgf抑制剂的嘧啶基芳基脲衍生物

    公开(公告)号：US20080312248A1

    公开(公告)日：2008-12-18

    申请号：US12158873

    申请日：2006-12-20

    申请人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    发明人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    IPC分类号： A61K31/5377 ,  C07D413/12 ,  A61K31/506 ,  C07D403/12 ,  A61K31/505 ,  C07D239/28 ,  A61P43/00

    CPC分类号： C07D239/48 ,  C07D401/12

    摘要： The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

    摘要翻译： 本发明涉及式IA的杂芳基芳基脲，其中基团和符号具有本文定义的含义，这些化合物在治疗蛋白激酶依赖性疾病中的用途; 涉及包含所述杂芳基芳基脲的药物制剂，以及制备这些新化合物的方法和包括使用这种杂芳基芳基脲的治疗方法。

    Pyrimidinyl aryl urea derivatives being FGF inhibitors
    13.
    发明授权
    Pyrimidinyl aryl urea derivatives being FGF inhibitors 有权
    嘧啶基芳基脲衍生物是FGF抑制剂

    公开(公告)号：US08293746B2

    公开(公告)日：2012-10-23

    申请号：US12158873

    申请日：2006-12-20

    申请人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    发明人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    IPC分类号： C07D403/12 ,  A61K31/505

    CPC分类号： C07D239/48 ,  C07D401/12

    摘要： The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

    摘要翻译： 本发明涉及式IA的杂芳基芳基脲，其中基团和符号具有本文定义的含义，这些化合物在治疗蛋白激酶依赖性疾病中的用途; 涉及包含所述杂芳基芳基脲的药物制剂，以及制备这些新化合物的方法和包括使用这种杂芳基芳基脲的治疗方法。

    Heterobicyclic carboxamides as inhibitors for kinases
    18.
    发明授权
    Heterobicyclic carboxamides as inhibitors for kinases 失效
    异环碳酰胺作为激酶抑制剂

    公开(公告)号：US08058276B2

    公开(公告)日：2011-11-15

    申请号：US12281715

    申请日：2007-03-09

    申请人： Guido Bold ,  Andrea Vaupel ,  Marc Lang

    发明人： Guido Bold ,  Andrea Vaupel ,  Marc Lang

    IPC分类号： C07D413/12 ,  C07D417/12 ,  A61K31/41

    CPC分类号： C07D413/12 ,  C07D403/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

    摘要： The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.

    摘要翻译： 本发明涉及式（I）的新型有机化合物及其在治疗动物或人体中的用途，包括式（I）化合物的药物组合物和式（I）化合物用于 制备用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，特别是肿瘤疾病的药物组合物。

    Cyclic diaryl ureas suitable as tyrosine kinase inhibitors
    19.
    发明授权
    Cyclic diaryl ureas suitable as tyrosine kinase inhibitors 失效
    适合作为酪氨酸激酶抑制剂的环状二芳基脲

    公开(公告)号：US07855215B2

    公开(公告)日：2010-12-21

    申请号：US11575601

    申请日：2005-09-27

    申请人： Guido Bold ,  Giorgio Caravatti ,  Andreas Floersheimer ,  Pascal Furet ,  Paul W Manley ,  Carole Pissot Soldermann ,  Andrea Vaupel

    发明人： Guido Bold ,  Giorgio Caravatti ,  Andreas Floersheimer ,  Pascal Furet ,  Paul W Manley ,  Carole Pissot Soldermann ,  Andrea Vaupel

    IPC分类号： A61K31/505 ,  A61K31/506 ,  C07D239/02 ,  C07D401/12 ,  C07D413/12

    CPC分类号： C07D417/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D417/14

    摘要： The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected from N or C—R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diary urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

    摘要翻译： 本发明涉及式I的新化合物：其中p是1,2或3; n为0,1,2或3; m为0,1,2或3; A是CRc，S，NRc或O，其中Rc是H或低级烷基; X，Y和Z各自独立地选自N或C-R 3，其中X，Y和Z中的至少两个是N; 并且每个R a独立地选自氢和低级烷基; 每个R b是氢或低级烷基; G是基团Ar或代表CN或未取代或取代的低级烷基; Ar是饱和或不饱和的环状基团，其是取代或未取代的，并且可以是五或六元单环或8,9,10,11或12元双环或三环，并且可以含有0,1,2或3个选自 来自O，N和S; 并且其中所述基团的R1，R2，R3和R4具有如本文所定义的含义，其盐，酯，N-氧化物或前药; 以及它们在治疗蛋白激酶依赖性疾病中的应用，它们在制备用于治疗所述疾病的药物组合物中的应用，用于治疗所述疾病的日用脲衍生物的使用方法，包含这些新型二芳基脲 衍生物，制备新型二芳基脲衍生物的方法，上述新型二芳基脲衍生物的使用或使用方法，和/或这些新型二芳基脲衍生物用于动物或人体的治疗。